Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Rhea-AI Summary

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the launch of Coeptis Technologies, a new division aimed at diversifying its business beyond biopharmaceuticals. The company has signed a binding Letter of Intent to acquire key assets from a Risk Mitigation Software Company with 10,000 customers across 100 countries.

The acquisition includes proprietary technologies such as Data Placement Manager and Sensitive Content Manager solutions. This move follows the upcoming acquisition of NexGenAI Affiliates Network, positioning Coeptis in the data security and AI technology sectors. The Risk Mitigation Software Company's CEO will join Coeptis to lead the new technology division, with the transaction expected to close in early 2025.

Positive

• Strategic expansion into high-growth technology sector through acquisition of established revenue-generating assets
• Immediate access to large customer base of 10,000 clients across 100 countries
• Acquisition of valuable proprietary data security technologies
• Experienced leadership joining from acquired company to manage new division

Negative

• Significant deviation from core biopharmaceutical business model
• Transaction completion subject to definitive agreements and approvals
• Potential integration risks between biotech and technology divisions

Insights

Financial Analyst

The strategic diversification into data security through asset acquisition marks a significant pivot for Coeptis. The deal brings immediate revenue potential with an established customer base of 10,000 clients across 100 countries. This expansion into technology, coupled with the upcoming NexGenAI acquisition, represents a major transformation from a pure-play biotech to a diversified technology-healthcare company. The move could help mitigate risks associated with the typically long development cycles in biotechnology.

The timing is particularly strategic given the robust growth in the data security sector. While specific financial terms aren't disclosed, the acquisition of revenue-generating assets could potentially improve Coeptis's cash flow position. However, investors should note the execution risks in managing two distinct business segments and the potential strain on resources for a company with a relatively small market cap of $7.4M.

Tech Expert

The acquisition brings valuable data security assets including Data Placement Manager and Sensitive Content Manager solutions, which are critical tools in today's data governance landscape. These technologies address growing concerns around data privacy and security compliance, particularly relevant given increasing regulatory requirements globally. The integration with NexGenAI's automation tools could create synergistic opportunities in streamlining data security operations.

The established customer base provides a strong foundation for market expansion, though maintaining and growing this base will require continued innovation and support. The retention of the current CEO to lead the technology division is important for maintaining operational continuity and customer relationships during the transition.

Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network

WEXFORD, Pa., Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential. This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors.

In line with this initiative, Coeptis Technologies has signed a binding Letter of Intent (LOI) with a Risk Mitigation Software Company who is a leading company in the data security software industry with over 10,000 customers in over 100 countries. This LOI outlines the acquisition of significant technology assets, representing a key step in broadening our operational scope and entering the burgeoning data security market.

The acquisition will involve the transfer of their proprietary technologies, including its Data Placement Manager and Sensitive Content Manager solutions, to Coeptis' newly established technology subsidiary. This development not only positions Coeptis as a formidable player in the data security field but also signals our dedication to innovation and long-term value creation for our shareholders. The transaction is anticipated to close upon the finalization of definitive agreements. The current President and CEO of the Risk Mitigation Software Company, will join Coeptis management team to lead this new technology division, ensuring that Coeptis leadership remains focused on both our biotechnology assets and the expansion into technology without distraction. This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors.

Dave Mehalick, President and CEO of Coeptis Therapeutics, commented, "We are embarking on an exciting journey of expansion that will not only enhance our presence in the biopharmaceutical sector but also venture into the high-growth technology sector. By establishing Coeptis Technologies, we are strategically positioning ourselves to leverage the unique opportunities present in these two dynamic industries. Our commitment to deliver unprecedented value to our shareholders is stronger than ever as we pursue innovative solutions that address the evolving needs of the market."

Dave Mehalick continued, "This acquisition represents a significant milestone in Coeptis' strategic evolution. By integrating the high-value technology assets of this new acquisition, we are obtaining well-established, revenue-generating assets that will enable us to position ourselves for long-term growth in the rapidly expanding data security industry. The acquisition will keep our new technology team very busy in the coming months as they bring over 10,000 customers in over 100 countries to Coeptis Technologies and they provide a modern approach to data governance and security by identifying and protecting all sensitive data regardless of location, platform, or format. Their framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies. The addition of these innovative data security solutions will not only diversify our portfolio but also allow us to explore new markets. We are particularly thrilled to welcome its CEO to our leadership team, as his expertise will be pivotal in maximizing the value of these assets and driving our next phase of growth, which aligns with our recently announced upcoming acquisition of NexGenAI Affiliates Network. More information on this acquisition will be announced in the coming weeks."

Dave Mehalick also commented on the NexGenAI acquisition, stating, "We are excited to integrate NexGenAI Affiliates Network and its groundbreaking AI and RPA-driven tools into our new technology division. This integration is poised to enhance the performance of both our biotechnology and technology sectors. In highly competitive industries such as biotech, pharma, and MLM, where regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial—it's essential for our success."

The asset acquisition of the Risk Mitigation Software Company is subject to customary closing conditions, including the execution of definitive agreements and requisite approvals by both parties. Coeptis anticipates completing this transaction in early 2025.

This strategic expansion into Coeptis Technologies comes at a pivotal time when the technology sector continues to experience rapid growth, with many of the market's top-performing stocks being technology-driven. By leveraging the innovative AI and RPA-driven tools from NexGenAI and the transformative data security technologies from the upcoming acquisition, Coeptis is not only diversifying its capabilities but is also positioning itself to thrive in one of the most dynamic and lucrative industries.

About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis visit [https://coeptistx.com/](https://coeptistx.com/).

About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexGenAI, visit [nexgenai.io](nexgenai.io).

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
For Coeptis Therapeutics, Inc.:
IR@coeptistx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-unveils-new-technology-division-coeptis-technologies-302329739.html

SOURCE Coeptis Therapeutics, Inc.

FAQ

What assets is Coeptis Technologies (COEP) acquiring in the Risk Mitigation Software deal?

Coeptis is acquiring proprietary technologies including Data Placement Manager and Sensitive Content Manager solutions, along with access to 10,000 customers across 100 countries.

When is the Coeptis Technologies (COEP) Risk Mitigation Software acquisition expected to close?

The acquisition is expected to close in early 2025, subject to definitive agreements and required approvals.

How does the Risk Mitigation Software acquisition align with COEP's NexGenAI acquisition?

Both acquisitions are part of Coeptis' strategy to expand into technology, combining data security solutions with AI and RPA-driven tools to enhance both biotechnology and technology operations.

What is the strategic significance of Coeptis (COEP) launching its Technologies division?

The launch represents a strategic diversification beyond biopharmaceuticals into the high-growth technology sector, aiming to maximize shareholder value through expansion into data security and AI technologies.